Thursday, July 2, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForevertodayHEALTHCARE340B Under Fire: The Hospital Drug Discount Fight That Hits CVS and HCA Where It Hurts4 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to WatchyesterdayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More PoliticalyesterdayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic ProducersyesterdayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In SpendingyesterdayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade2 days agoCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation3 days agoCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream3 days agoCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It4 days agoCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program5 days agoCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes5 days agoCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil6 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers2 weeks agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centruslast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two2 weeks agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactorslast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare

The Biosimilar Promotion Trade: When FDA Pushes Interchangeability, Pfizer Collects

FDA's accelerating push to grant biosimilars interchangeability status quietly dismantles branded biologic moats — and hands Pfizer a structural volume windfall at Lilly and Novo Nordisk's expense.

Image: Money Racket
By at Money Racket · Jun 1, 2026

The FDA's Purple Book isn't bedside reading, but it's where money moves in pharmaceutical markets. Under its Biologics Price Competition and Innovation Act authority, the FDA awards "interchangeability" designations to biosimilars that meet a strict switching standard — meaning pharmacists can substitute them for branded biologics without a physician's go-ahead, the same dispensing freedom generics have long enjoyed in small-molecule drugs. The agency has been accelerating that pipeline, publishing guidance updates and working through a growing queue of applicants. Every new interchangeability stamp chips away at the automatic pharmacy loyalty that has shielded branded biologic revenue for a decade.

The mechanism is structural: interchangeable biosimilars pull market share not through physician prescribing decisions but through pharmacy-level substitution, bypassing the sales-rep moat that protects branded drugs. Formulary pressure from PBMs and payers amplifies the effect — once a biosimilar is interchangeable, plan sponsors have contractual leverage to mandate the switch.

Every new interchangeability stamp chips away at the automatic pharmacy loyalty that has shielded branded biologic revenue for a decade.

Who cashes in

PFE (Pfizer) is the clearest winner. Pfizer operates one of the largest biosimilar franchises in the U.S. through its Hospira acquisition, with approved biosimilars across oncology supportive care, inflammation, and ophthalmology. Interchangeability designations on products like Biosimilar Humira competitors and infliximab products mean pharmacy-level pull-through that doesn't require detailing. Volume comes to Pfizer as branded defenders' moats erode.

CVS (CVS Health) benefits on two fronts. Its Caremark PBM unit gains negotiating leverage with branded manufacturers the moment an interchangeable alternative exists — either extracting deeper rebates or steering volume. Its retail pharmacy network also captures the dispensing economics when pharmacists exercise substitution rights.

UNH (UnitedHealth Group) wins through Optum Rx, its PBM arm. Payer control of formulary tier placement is the primary mechanism by which interchangeable biosimilars gain volume, and Optum Rx sits at that lever. Lower net drug costs flow directly to medical loss ratio improvement.

Who is exposed

LLY (Eli Lilly) carries meaningful biologic revenue exposure, particularly as its incretin franchise matures and older biologics face biosimilar competition. Interchangeability designations on any product facing a Lilly anchor drug compress net pricing power regardless of gross list price.

NVO (Novo Nordisk) faces biosimilar insulin and, looking ahead, GLP-1 biosimilar entrants. Interchangeability on insulin products already pressures Novo's U.S. margin structure, and the FDA pathway is clearly widening.

What to watch

Track the FDA's Purple Book database for new interchangeability approvals and the agency's draft guidance documents on switching studies — these are the leading indicator before the market reprices. Watch Pfizer's biosimilars segment revenue line each quarter; acceleration there is the confirming signal. PBM contract renewal seasons (typically Q4) are when formulary shifts driven by new designations become binding on patient volumes.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →